Quantcast
Last updated on April 24, 2014 at 1:21 EDT

Latest CytRx Corporation Stories

2014-03-24 16:24:59

In the news release, Attention CytRx Corporation Investors: CytRx Misled Investors According to a Recently Filed Class Action, issued 21-Mar-2014 by Robbins Arroyo LLP over PR Newswire, we are advised by the company that the third paragraph should read that Steven A. Kriegsman sold $2.1 million of Galena Biopharma, Inc. shares, not CytRx shares as originally issued. The complete, corrected release follows: Attention CytRx Corporation Investors: CytRx Misled Investors According to a...

2014-03-21 20:21:48

SAN DIEGO and LOS ANGELES, March 21, 2014 /PRNewswire/ -- Shareholder rights law firm Robbins Arroyo LLP announces that an investor of CytRx Corporation (NASDAQ: CYTR) has filed a federal securities fraud class action complaint in the U.S. District Court for the Central District of California. The complaint alleges that the company and certain of its officers and directors violated the Securities and Exchange Act of 1934 between November 22, 2013 and March 13, 2014, including the...

2013-12-24 08:23:28

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, December 24, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Humana Inc. (NYSE: HUM), Illumina Inc. (NASDAQ: ILMN), Edwards Lifesciences Corp. (NYSE: EW), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR) and CytRx Corporation (NASDAQ: CYTR). Today's readers may access these reports free of charge - including full price targets, industry analysis and...

2008-11-11 09:00:08

CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced that INNO-406, CytRx's potent, orally available, rationally designed, dual Bcr-Abl and Lyn-kinase inhibitor, demonstrated clinical responses in patients with Chronic Myeloid Leukemia (CML). INNO-406 is being evaluated for the treatment of patients with CML and other leukemias that have a certain mutation called the Philadelphia Chromosome (Ph+)...

2008-10-15 09:00:47

CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced that its 45% owned affiliate RXi Pharmaceuticals Corporation has licensed exclusive worldwide rights from the University of Massachusetts Medical School (UMMS) to certain technology for the oral delivery of RNAi therapeutics. The technology was developed by Dr. Michael Czech, Professor and Chair, Program in Molecular Medicine at UMMS and an RXi...

2008-09-22 09:00:12

CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced the completion of its acquisition of Innovive Pharmaceuticals, Inc. CytRx purchased Innovive for total consideration of approximately 2.6 million shares of CytRx common stock, approximately $18.3 million of future performance-based milestone earn-outs, and the assumption of Innovive's liabilities. The acquired Innovive portfolio...

2008-08-12 09:01:37

CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company engaged in the development and commercialization of therapeutics based on molecular chaperone amplification, today reported financial results for the three months ended June 30, 2008 and other second quarter developments. "During the second quarter, we announced the signing of a definitive agreement to purchase Innovive Pharmaceuticals, Inc.," said Steven A. Kriegsman, CytRx President and CEO. "The acquisition is a compelling...

2004-12-01 09:00:08

LOS ANGELES, Dec. 1 /PRNewswire-FirstCall/ -- CytRx Corporation announced that its orally available drug candidate, iroxanadine, was effective in treating cardiovascular disease in an experimental mouse model for atherosclerosis. The experiments demonstrated that iroxanadine significantly reduced plaque formation and arterial thickening in mice, both of which are symptoms that lead to serious cardiovascular disease. According to the National Heart, Lung & Blood Institute,...